Stockscreener 앱 받기
2.29
11.17%
0.23
시간 외 거래:
2.18
-0.11
-4.80%
전일 마감가:
$2.06
열려 있는:
$2.04
하루 거래량:
3.35M
Relative Volume:
1.29
시가총액:
$68.16M
수익:
-
순이익/손실:
$-13.08M
주가수익비율:
-5.1857
EPS:
-0.4416
순현금흐름:
-
1주 성능:
+89.26%
1개월 성능:
+30.11%
6개월 성능:
-54.47%
1년 성능:
-43.73%
1일 변동 폭
$2.04
$2.44
1주일 범위
$2.025
$3.10
52주 변동 폭
$1.12
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
TELO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.29 | 61.31M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
When is the best time to buy Telomir Pharmaceuticals Inc. stockSuperior risk-adjusted returns - jammulinksnews.com
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathway - Reno Gazette Journal
Telomir Pharmaceuticals stock surges on promising Progeria treatment results - Investing.com
Telomir-1 shows promise in restoring mitochondrial function By Investing.com - Investing.com South Africa
Telomir-1 shows promise in restoring mitochondrial function - Investing.com Australia
Revolutionary Mitochondrial Drug Could Transform Treatment of Alzheimer's, Parkinson's, and ALS - Stock Titan
Telomir Pharmaceuticals Inc. Stock Analysis and ForecastExceptional trading results - Autocar Professional
Telomir Pharmaceuticals Inc (NASDAQ: TELO) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Telomir Pharmaceuticals Inc (TELO) Stock: A Year of Stock Market Dynamics - investchronicle.com
What analysts say about Telomir Pharmaceuticals Inc. stockSuperior returns - jammulinksnews.com
Is Telomir Pharmaceuticals Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com
What drives Telomir Pharmaceuticals Inc. stock priceDynamic profit opportunities - jammulinksnews.com
What makes Telomir Pharmaceuticals Inc. stock price move sharplyGrowth Stock Monitor - Newser
Pre-market Movers: PMN, GCTK, TELO, SRPT... - RTTNews
Why Is Telomir Pharmaceuticals Stock (TELO) Up 150% Today? - MSN
Healthcare Stocks Move in Pre-Market Session: Telomir Pharmaceuticals, Mesoblast, and More - AInvest
Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin - Lohud
Telomir Pharmaceuticals Stock Price, Quotes and Forecasts - Benzinga
Telomir skyrockets on preclinical data backing epigenetic potential of lead asset - FirstWord Pharma
Dow Falls Over 200 Points; 3M Earnings Top Views - Benzinga
Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests - NewsBreak: Local News & Alerts
Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results - MSN
Telomir Pharmaceuticals: A Disruptive Force in Prostate Cancer Therapy with Epigenetic Innovation - AInvest
Telomir Pharmaceuticals stock soars after promising cancer treatment data - Investing.com
Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains - Stocktwits
Telomir Pharmaceuticals stock soars after promising cancer treatment data By Investing.com - Investing.com UK
Cancer Breakthrough Sends Telomir Pharma Stock Exploding 157% - Wall Street Pit
Telomir-1 shows stronger epigenetic effects than standard drugs in cancer study - Investing.com Australia
Telomir-1 shows stronger epigenetic effects than standard drugs in cancer study By Investing.com - Investing.com South Africa
Revolutionary Cancer Treatment Shows 50% Tumor Reduction, Beats Standard Chemotherapy in Clinical Tests - Stock Titan
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
1.57%
자본화:
|
볼륨(24시간):